837 related articles for article (PubMed ID: 29674797)
21. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
[TBL] [Abstract][Full Text] [Related]
22. Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
Bhushan S; Ray RS; Prakash J; Singh GN
Clin Ther; 2019 Nov; 41(11):2252-2262. PubMed ID: 31543285
[TBL] [Abstract][Full Text] [Related]
23. Development of Pharmacovigilance System in India and Paradigm of Pharmacovigilance Research: An Overview.
Singh P; Vaishnav Y; Verma S
Curr Drug Saf; 2023; 18(4):448-464. PubMed ID: 36200243
[TBL] [Abstract][Full Text] [Related]
24. Adverse Drug Reactions in Hospitalized Pediatric Patients: A Prospective Observational Study.
Kurian J; Mathew J; Sowjanya K; Chaitanya KR; Ramesh M; Sebastian J; Narayanappa D
Indian J Pediatr; 2016 May; 83(5):414-9. PubMed ID: 26916890
[TBL] [Abstract][Full Text] [Related]
25. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden.
Holm L; Ekman E; Jorsäter Blomgren K
Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):335-343. PubMed ID: 28071845
[TBL] [Abstract][Full Text] [Related]
26. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
[TBL] [Abstract][Full Text] [Related]
27. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
Castillon G; Salvo F; Moride Y
Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
[TBL] [Abstract][Full Text] [Related]
28. The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.
Karlsson SA; Jacobsson I; Boman MD; Hakkarainen KM; Lövborg H; Hägg S; Jönsson AK
Eur J Clin Pharmacol; 2015 May; 71(5):631-6. PubMed ID: 25845655
[TBL] [Abstract][Full Text] [Related]
29. Adverse drug reactions in a psychiatric department of tertiary care teaching hospital in India: Analysis of spontaneously reported cases.
Patel TK; Bhabhor PH; Desai N; Shah S; Patel PB; Vatsala E; Panigrahi S
Asian J Psychiatr; 2015 Oct; 17():42-9. PubMed ID: 26216702
[TBL] [Abstract][Full Text] [Related]
30. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
31. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
[TBL] [Abstract][Full Text] [Related]
32. Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa.
Jones J; Swart A; Tommy E; Cohen K; Stewart A; Voget J; Blockman M
S Afr Med J; 2020 Nov; 110(12):1226-1230. PubMed ID: 33403970
[TBL] [Abstract][Full Text] [Related]
33. Adverse Drug Reactions Spontaneously Reported at a Tertiary Care Hospital and Preventable Measures Implemented.
Abu Esba LC; Al Mardawi G; AlJasser MI; Aljohani B; Abu Alburak A
J Clin Pharm Ther; 2021 Apr; 46(2):460-469. PubMed ID: 33285001
[TBL] [Abstract][Full Text] [Related]
34. Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs.
Tabali M; Ostermann T; Jeschke E; Witt CM; Matthes H
J Manag Care Pharm; 2012; 18(6):427-38. PubMed ID: 22839683
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic monoclonal antibodies and the need for targeted pharmacovigilance in India.
Kalaivani M; Singh A; Kalaiselvan V
MAbs; 2015; 7(1):276-80. PubMed ID: 25523367
[TBL] [Abstract][Full Text] [Related]
36. Statistical Signal Process in R Language in the Pharmacovigilance Programme of India.
Kumar A; Ahuja J; Shrivastava TP; Kumar V; Kalaiselvan V
Ther Innov Regul Sci; 2018 May; 52(3):329-333. PubMed ID: 29714534
[TBL] [Abstract][Full Text] [Related]
37. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme.
Carnovale C; Gentili M; Fortino I; Merlino L; Clementi E; Radice S; ViGer Group
Expert Opin Drug Saf; 2016; 15(2):131-9. PubMed ID: 26882049
[TBL] [Abstract][Full Text] [Related]
38. An Evaluation of Indian Consumers' Reporting of Suspected Adverse Drug Reactions with a Designated Reporting Form.
Rehan HS; Sah R; Gupta A; Nagar P
Curr Drug Saf; 2017; 12(1):51-56. PubMed ID: 27188794
[TBL] [Abstract][Full Text] [Related]
39. Analysis of Reporting Adverse Drug Reactions in Paediatric Patients in a University Hospital in the Netherlands.
Dittrich ATM; Draaisma JMT; van Puijenbroek EP; Loo DMWMT
Paediatr Drugs; 2020 Aug; 22(4):425-432. PubMed ID: 32557243
[TBL] [Abstract][Full Text] [Related]
40. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
